HerniaNCT01845376
Local or Regional or General Anesthesia for Hernia Repair: a Randomized Controlled Trial
A study testing local anesthesia group, spinal anesthesia group and general anesthesia group in people with Hernia and Anesthetics Adverse Reaction, run by Mingkwan Wongyingsinn, MD at 1 site in Thailand.
Trial summary
This present randomized trial is designed to evaluate the postoperative pain,inflammatory marker, postoperative analgesic medication, length of hospital stay and the modifications of inflammatory mediators in patients undergoing inguinal hernia repair using local, spinal or general anesthesia. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hernia, Anesthetics Adverse Reaction, Inflammation
- What is being tested?
- local anesthesia group, spinal anesthesia group and general anesthesia group
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 1 siteThailand
- Study dates
- Apr 2014to Nov 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients scheduled to undergo elective unilateral inguinal hernia repair at Siriraj Hospital will be undertaken.
- ASA I-III,
- Age greater than 18 years old
Who cannot join
- Allergy to any medication used this study,
- Femoral hernia, recurrent hernia, bilateral hernia,
- Bleeding abnormalities,
- Severe hepatic, renal or cardiovascular disease,
- Chronic use of opioid,
- History of using steroidal or nonsteroidal anti-inflammatory drugs in the past 6 months,
- Inability to communicate in Thai or to understand the purpose of the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Postoperative Clinical Outcomes and Inflammatory Markers After Inguinal Hernia Repair With Local or Spinal or General Anesthesia: A Randomized Trial
This present randomized trial is designed to evaluate the postoperative pain,inflammatory marker, postoperative analgesic medication, length of hospital stay and the modifications of inflammatory mediators in patients undergoing inguinal hernia repair using local, spinal or general anesthesia.
Read the detailed description
After approval by Siriraj Institutional Review Board, a prospective randomized study in patients scheduled to undergo elective unilateral inguinal hernia repair at Siriraj Hospital will be undertaken. Patients, ASA I-III, greater than 18 years old will be approached in the outpatient surgical department and recruited in this study. Informed written consent will be obtained from each of them. Exclusion criteria are allergy to any medication used this study, femoral hernia, recurrent hernia, bilateral hernia, bleeding abnormalities, severe hepatic, renal or cardiovascular disease, chronic use of opioid, history of using steroidal or nonsteroidal anti-inflammatory drugs in the past 6 months, inability to communicate in Thai or to understand the purpose of the study.
Anesthesia and surgical procedure
All patients will be admitted one day before operation as routine and receive no premedication. Patients will be randomly allocated in the morning of the operation to receive one of the three anesthetic techniques: local anesthesia (LA), spinal anesthesia (SA) or general anesthesia (GA) for their inguinal hernia repair. The randomization process will be done by the use of a computer-generated number sealed in a brown envelope. All the patients will undergo standardized inguinal hernia repairs by three surgeons, A Trakarnsanga; V Chinsawangtanakul; T Akaraviputh, who agree to follow a precise protocol using Lichtenstein technique as described by Amid.
In the LA group, patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine. Surgeons will be taught to do the local anesthetic technique in a standardized manner.
In the SA group, patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected. Sensory block (T4 and below dermatomes) to cold and pinprick will be tested before starting operation. An incremental dose containing 1 mg of midazolam and 25 mcg of fentanyl will be intravenously given if patients in the LA and SA group require.
In the GA group, patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
For postoperative analgesia, all groups will receive infiltration 10 ml of 0.5% into the surgical wounds. They will also receive oral acetaminophen two tablets every 6 hours and Arcoxia® (etoricoxib) 60-90 mg daily unless contraindicated for the duration of their hospital stay. Intravenous morphine 1-2 mg will be provided every 4 hours as a breakthrough medication.
For hospital discharge, patients will be allowed to discharge home when they fulfill criteria: obtain and self-administer medications; perform self-care activities; eat an appropriate diet or otherwise manage nutritional needs; follow-up with designated providers.
A blood sample 7 mL will be taken at antecubital vein with aseptic technique, proper decontamination procedures and needle 22-gauge on the preoperative day, at 8 and 24 hours after completion of the surgery. Blood samples will be collected in tubes without anticoagulant to perform interleukin-1 beta (IL-1 beta), IL-6 and IL-10 assays. All blood samples will be centrifuged for 15 min at 1000g. Serum will be stored at -80 °C until performing assay for cytokines. The IL-1 beta, IL-6 and IL-10 will be assessed in the serum with LEGEND MAX Human Interleukin ELISA Kit (Biolegend, USA). Briefly, the quantitative sandwich enzyme immunoassay technique uses monoclonal antibodies specific for IL-1 beta or IL-6 or IL-10. Serum concentrations will be calculated by using regression analysis with standard curves and expressed as picograms per milliliter (pg /ml). All samples will be measured in duplicate, with averages used in the statistical analyses. The minimum detectable concentrations IL-1 beta, IL-6 and IL-10 are 0.5 pg /ml, 1.6 pg /ml and 2 pg /ml, respectively.
All the perioperative data will be collected from patients' chart and filled in case record form by one of the authors. The ward nurses round and the postoperative anesthetic nurses round will follow the care pathway as routine. Patients have no restrictions on activities, and they are encouraged to resume work and normal daily activities as soon as possible. Patients are discharged in accordance with routine at our respective hospital.
The following data will be collected: demographic characteristics, diagnosis, duration of anesthesia and surgery, conversion to other anesthetic techniques or other operations, quality of pain relief, postoperative use of analgesics and amount of analgesic medication, intraoperative and postoperative complications, incidence of postoperative nausea and vomiting (PONV), length of postoperative hospital stay, acute inflammatory markers, patient satisfaction, incidence of complications and readmission rate during 30 days after the operation. Complications are defined as bleeding or hematoma necessitating reoperation or compression bandage, urinary retention that requires catheterization, fever > 38°Celsius requiring medication treatment.
Primary outcomes are postoperative pain at rest and on mobilization at postoperative 8 and 24 as measured with verbal rating score (VRS) from 0 (no pain) to 10 (worst pain). Secondary outcome measures are acute inflammatory markers. Intermediate outcomes include duration of anesthesia and surgery, conversion to other anesthetic techniques, postoperative use of analgesics and amount of analgesic medication, incidence of nausea and vomiting, length of postoperative hospital stay in the unit of hour, patient satisfaction measured with verbal rating score (VRS) from 0 (worst) to 100 (best), incidence of complications and readmission rate during 30 days after the operation.
The primary outcome is postoperative pain on mobilization at 24 after the operation. The sample size is based on two previous studies, which the pain scores of patients having local anesthesia is 5.2 (SD=4.38), spinal anesthesia is 4.0 (SD=2.08) and general anesthesia is 7.2 (SD=1.73), a calculation is done to obtain a type I error of 0.05 and a power of 80% with a balanced Analysis Of Variance test (ANOVA) using nQuery Advisor version 7.0 (Statistical Solutions, Cork, Ireland).2, 4 The calculated sample size per group is 15 patients and the number is increased to 18 patients per groups to include 20% dropouts.
Categorical variables are analyzed by X2 test. Continuous variables are presented as mean and standard deviation (SD) or median and interquartile range (IQR) when data are not normal distribution. Comparison between groups used either ANOVA with Bonferroni's post hoc test or Kruskall Wallis test when data are not normally distributed. All statistical tests are two tailed and P value less than 0.05 is considered significant for all data. Statistical analysis is performed using SPSS version 18 for Windows (SPSS Inc., Chicago, IL).
- Conditions
- Hernia, Anesthetics Adverse Reaction, Inflammation
- Being tested
- local anesthesia group, spinal anesthesia group, general anesthesia group
- Keywords
- Inflammatory Markers after Inguinal Hernia Repair, Anesthetic technique for hernia repair
- Medical subject headings
- Hernia, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
local anesthesia groupProcedure or surgery
Also called LA group
Patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine.
spinal anesthesia groupProcedure or surgery
Also called SA group
Patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected.
general anesthesia groupProcedure or surgery
Also called GA group
Patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
| Study group | Role | What they receive |
|---|---|---|
| local anesthesia group | Experimental | In the local anesthesia group, patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine. Surgeons will be taught to do the local anesthetic technique in a standardized manner. Receives: Procedure: local anesthesia group |
| spinal anesthesia group | Experimental | In the spinal anesthesia group, patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected. Sensory block (T4 and below dermatomes) to cold and pinprick will be tested before starting operation. An incremental dose containing 1 mg of midazolam and 25 mcg of fentanyl will be intravenously given if patients in the LA and SA group require. Receives: Procedure: spinal anesthesia group |
| general anesthesia group | Experimental | In the general anesthesia group, patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline. Receives: Procedure: general anesthesia group |
What is being measured
The primary outcome is the main question the study is designed to answer.
postoperative pain on mobilization
postoperative pain on mobilization at postoperative 8 hour. postoperative pain is measured with verbal rating score (VRS) from 0 (no pain) to 10 (worst pain).
Measured: at postoperative 8 hours
Secondary outcomes (3)
acute inflammatory markers (IL-1 beta)
All samples will be measured in duplicate, with averages used in the statistical analyses. The minimum detectable concentrations IL-1 beta, IL-6 and IL-10 are 0.5 pg /ml, 1.6 pg /ml and 2 pg /ml, respectively.
Measured: at 8 hours after surgery
acute inflammatory markers (IL-6)
All samples will be measured in duplicate, with averages used in the statistical analyses.
Measured: at 8 hours after surgery
acute inflammatory markers (IL-10)
All samples will be measured in duplicate, with averages used in the statistical analyses.
Measured: at 8 hours after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2013 (estimated)
- Study startApr 2014
- Primary completionNov 2015
- Study completionNov 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HerniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mingkwan Wongyingsinn, MD
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Mingkwan Wongyingsinn, MD, Siriraj Hospital
- Investigators
- Mingkwan Wongyingsinn, MD, MSc, Principal investigator, Department of Anesthesiology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01845376
- Sponsor's protocol ID
- SIRB035
- Status last verified
- Jul 2016
- First submitted
- 26 Apr 2013
- Last updated
- 29 Jul 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Postoperative Clinical Outcomes and Inflammatory Markers After Inguinal Hernia Repair With Local or Spinal or General Anesthesia: A Randomized Trial
- ClinicalTrials.gov ID
- NCT01845376
- Acronym / sponsor ID
- SIRB035
- Conditions
- Hernia, Anesthetics Adverse Reaction, Inflammation
- Keywords
- Inflammatory Markers after Inguinal Hernia Repair, Anesthetic technique for hernia repair
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- Mingkwan Wongyingsinn, MDUniversity, hospital or other
- Study start
- Apr 2014
- Primary completion
- Nov 2015 (actual)
- Study completion
- Nov 2015 (actual)
- First posted
- 3 May 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This present randomized trial is designed to evaluate the postoperative pain,inflammatory marker, postoperative analgesic medication, length of hospital stay and the modifications of inflammatory mediators in patients undergoing inguinal hernia repair using local, spinal or general anesthesia.
Detailed description
After approval by Siriraj Institutional Review Board, a prospective randomized study in patients scheduled to undergo elective unilateral inguinal hernia repair at Siriraj Hospital will be undertaken. Patients, ASA I-III, greater than 18 years old will be approached in the outpatient surgical department and recruited in this study. Informed written consent will be obtained from each of them. Exclusion criteria are allergy to any medication used this study, femoral hernia, recurrent hernia, bilateral hernia, bleeding abnormalities, severe hepatic, renal or cardiovascular disease, chronic use of opioid, history of using steroidal or nonsteroidal anti-inflammatory drugs in the past 6 months, inability to communicate in Thai or to understand the purpose of the study.
Anesthesia and surgical procedure
All patients will be admitted one day before operation as routine and receive no premedication. Patients will be randomly allocated in the morning of the operation to receive one of the three anesthetic techniques: local anesthesia (LA), spinal anesthesia (SA) or general anesthesia (GA) for their inguinal hernia repair. The randomization process will be done by the use of a computer-generated number sealed in a brown envelope. All the patients will undergo standardized inguinal hernia repairs by three surgeons, A Trakarnsanga; V Chinsawangtanakul; T Akaraviputh, who agree to follow a precise protocol using Lichtenstein technique as described by Amid.
In the LA group, patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine. Surgeons will be taught to do the local anesthetic technique in a standardized manner.
In the SA group, patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected. Sensory block (T4 and below dermatomes) to cold and pinprick will be tested before starting operation. An incremental dose containing 1 mg of midazolam and 25 mcg of fentanyl will be intravenously given if patients in the LA and SA group require.
In the GA group, patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
For postoperative analgesia, all groups will receive infiltration 10 ml of 0.5% into the surgical wounds. They will also receive oral acetaminophen two tablets every 6 hours and Arcoxia® (etoricoxib) 60-90 mg daily unless contraindicated for the duration of their hospital stay. Intravenous morphine 1-2 mg will be provided every 4 hours as a breakthrough medication.
For hospital discharge, patients will be allowed to discharge home when they fulfill criteria: obtain and self-administer medications; perform self-care activities; eat an appropriate diet or otherwise manage nutritional needs; follow-up with designated providers.
A blood sample 7 mL will be taken at antecubital vein with aseptic technique, proper decontamination procedures and needle 22-gauge on the preoperative day, at 8 and 24 hours after completion of the surgery. Blood samples will be collected in tubes without anticoagulant to perform interleukin-1 beta (IL-1 beta), IL-6 and IL-10 assays. All blood samples will be centrifuged for 15 min at 1000g. Serum will be stored at -80 °C until performing assay for cytokines. The IL-1 beta, IL-6 and IL-10 will be assessed in the serum with LEGEND MAX Human Interleukin ELISA Kit (Biolegend, USA). Briefly, the quantitative sandwich enzyme immunoassay technique uses monoclonal antibodies specific for IL-1 beta or IL-6 or IL-10. Serum concentrations will be calculated by using regression analysis with standard curves and expressed as picograms per milliliter (pg /ml). All samples will be measured in duplicate, with averages used in the statistical analyses. The minimum detectable concentrations IL-1 beta, IL-6 and IL-10 are 0.5 pg /ml, 1.6 pg /ml and 2 pg /ml, respectively.
All the perioperative data will be collected from patients' chart and filled in case record form by one of the authors. The ward nurses round and the postoperative anesthetic nurses round will follow the care pathway as routine. Patients have no restrictions on activities, and they are encouraged to resume work and normal daily activities as soon as possible. Patients are discharged in accordance with routine at our respective hospital.
The following data will be collected: demographic characteristics, diagnosis, duration of anesthesia and surgery, conversion to other anesthetic techniques or other operations, quality of pain relief, postoperative use of analgesics and amount of analgesic medication, intraoperative and postoperative complications, incidence of postoperative nausea and vomiting (PONV), length of postoperative hospital stay, acute inflammatory markers, patient satisfaction, incidence of complications and readmission rate during 30 days after the operation. Complications are defined as bleeding or hematoma necessitating reoperation or compression bandage, urinary retention that requires catheterization, fever > 38°Celsius requiring medication treatment.
Primary outcomes are postoperative pain at rest and on mobilization at postoperative 8 and 24 as measured with verbal rating score (VRS) from 0 (no pain) to 10 (worst pain). Secondary outcome measures are acute inflammatory markers. Intermediate outcomes include duration of anesthesia and surgery, conversion to other anesthetic techniques, postoperative use of analgesics and amount of analgesic medication, incidence of nausea and vomiting, length of postoperative hospital stay in the unit of hour, patient satisfaction measured with verbal rating score (VRS) from 0 (worst) to 100 (best), incidence of complications and readmission rate during 30 days after the operation.
The primary outcome is postoperative pain on mobilization at 24 after the operation. The sample size is based on two previous studies, which the pain scores of patients having local anesthesia is 5.2 (SD=4.38), spinal anesthesia is 4.0 (SD=2.08) and general anesthesia is 7.2 (SD=1.73), a calculation is done to obtain a type I error of 0.05 and a power of 80% with a balanced Analysis Of Variance test (ANOVA) using nQuery Advisor version 7.0 (Statistical Solutions, Cork, Ireland).2, 4 The calculated sample size per group is 15 patients and the number is increased to 18 patients per groups to include 20% dropouts.
Categorical variables are analyzed by X2 test. Continuous variables are presented as mean and standard deviation (SD) or median and interquartile range (IQR) when data are not normal distribution. Comparison between groups used either ANOVA with Bonferroni's post hoc test or Kruskall Wallis test when data are not normally distributed. All statistical tests are two tailed and P value less than 0.05 is considered significant for all data. Statistical analysis is performed using SPSS version 18 for Windows (SPSS Inc., Chicago, IL).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| local anesthesia group | Experimental | Procedure: local anesthesia groupIn the local anesthesia group, patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine. Surgeons will be taught to do the local anesthetic technique in a standardized manner. |
| spinal anesthesia group | Experimental | Procedure: spinal anesthesia groupIn the spinal anesthesia group, patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected. Sensory block (T4 and below dermatomes) to cold and pinprick will be tested before starting operation. An incremental dose containing 1 mg of midazolam and 25 mcg of fentanyl will be intravenously given if patients in the LA and SA group require. |
| general anesthesia group | Experimental | Procedure: general anesthesia groupIn the general anesthesia group, patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients scheduled to undergo elective unilateral inguinal hernia repair at Siriraj Hospital will be undertaken.
- ASA I-III,
- Age greater than 18 years old
Key exclusion criteria (7 listed)
- Allergy to any medication used this study,
- Femoral hernia, recurrent hernia, bilateral hernia,
- Bleeding abnormalities,
- Severe hepatic, renal or cardiovascular disease,
- Chronic use of opioid,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| local anesthesia groupAlso: LA groupPatients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine. | Procedure or surgery | local anesthesia group |
| spinal anesthesia groupAlso: SA groupPatients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected. | Procedure or surgery | spinal anesthesia group |
| general anesthesia groupAlso: GA groupPatients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline. | Procedure or surgery | general anesthesia group |
Primary outcome
postoperative pain on mobilization
Time frame: at postoperative 8 hours
postoperative pain on mobilization at postoperative 8 hour. postoperative pain is measured with verbal rating score (VRS) from 0 (no pain) to 10 (worst pain).
3 secondary outcomes
acute inflammatory markers (IL-1 beta)
Time frame: at 8 hours after surgery
acute inflammatory markers (IL-6)
Time frame: at 8 hours after surgery
acute inflammatory markers (IL-10)
Time frame: at 8 hours after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2016.
- Individual participant dataSharing planned: No
Related trials for Hernia
Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
Enrolling by invitationObservational study
North American Fetal Therapy Network Prospective Registry for Long-term Outcome Following Fetoscopic Endoluminal Tracheal Occlusion in Severe Left and Right Congenital Diaphragmatic Hernia
Congenital Diaphragmatic Hernia
Recruiting
Permanent Versus Slowly Dissolving Stitches for Non-Mesh (Shouldice) Groin Hernia Repair
Inguinal Hernia
Recruiting
Fetal Repair of Complex Gastroschisis: A Safety and Feasibility Trial
Gastroschisis
Recruiting
Duramesh Versus Minimally Invasive IPOM for High-Risk Umbilical Hernia Repairs
Umbilical Hernia, Ventral Hernia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mingkwan Wongyingsinn, MD, MSc principal investigator
Department of Anesthesiology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing local anesthesia group, spinal anesthesia group and general anesthesia group in people with Hernia and Anesthetics Adverse Reaction, run by Mingkwan Wongyingsinn, MD at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
postoperative pain on mobilization (time frame: at postoperative 8 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2016.